"Tax Avoidance: U.S. Drug Makers' Profits Soar Despite Low Corporate Tax Payments"

Many large U.S. pharmaceutical companies, including Pfizer, are paying taxes well below the 21% corporate tax rate, with some even reporting losses despite significant domestic sales. This is achieved through complex tax strategies involving offshore subsidiaries and intellectual property licensing. Despite efforts to change this, it is unlikely to see significant change in the near future.